- Home
- Publications
- Publication Search
- Publication Details
Title
The Role of TLRs in Anti-cancer Immunity and Tumor Rejection
Authors
Keywords
-
Journal
Frontiers in Immunology
Volume 10, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2019-10-22
DOI
10.3389/fimmu.2019.02388
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Toll-like receptor 2 and Toll-like receptor 4 exhibit distinct regulation of cancer cell stemness mediated by cell death-induced high-mobility group box 1
- (2019) Xuelian Chen et al. EBioMedicine
- The Therapeutic Strategies of Regulatory T Cells in Malignancies and Stem Cell Transplantations
- (2019) Rana G. Zaini et al. Journal of Oncology
- Mass Spectrometry-based Structural Analysis and Systems Immunoproteomics Strategies for Deciphering the Host Response to Endotoxin
- (2018) Mohd M. Khan et al. JOURNAL OF MOLECULAR BIOLOGY
- MyD88 and TLR4 Expression in Epithelial Ovarian Cancer
- (2018) Matthew S. Block et al. MAYO CLINIC PROCEEDINGS
- The revival of CpG oligonucleotide-based cancer immunotherapies
- (2018) Tomasz Adamus et al. Wspolczesna Onkologia-Contemporary Oncology
- Role of TLR4 as a prognostic factor for survival in various cancers: a meta-analysis
- (2018) Bo Hao et al. Oncotarget
- Bacterial Therapy of Cancer: Promises, Limitations, and Insights for Future Directions
- (2018) M. Gabriela Kramer et al. Frontiers in Microbiology
- Editorial: Immunotherapy for Tumor in the Brain: Insights From—and For—Other Tumor Sites
- (2018) Lois A. Lampson Frontiers in Oncology
- Dual functional roles of the MyD88 signaling in colorectal cancer development
- (2018) Lu Wang et al. BIOMEDICINE & PHARMACOTHERAPY
- The Role of Toll-Like Receptor in Inflammation and Tumor Immunity
- (2018) Xiaohong Cen et al. Frontiers in Pharmacology
- Molecular Repolarisation of Tumour-Associated Macrophages
- (2018) Floris van Dalen et al. MOLECULES
- Both Type I and Type II Interferons Can Activate Antitumor M1 Macrophages When Combined With TLR Stimulation
- (2018) Elisabeth Müller et al. Frontiers in Immunology
- Toll-like receptor stimulation in cancer: A pro- and anti-tumor double-edged sword
- (2017) Marion Dajon et al. IMMUNOBIOLOGY
- Alarmins and immunity
- (2017) De Yang et al. IMMUNOLOGICAL REVIEWS
- Is the blood–brain barrier really disrupted in all glioblastomas? A critical assessment of existing clinical data
- (2017) Jann N Sarkaria et al. NEURO-ONCOLOGY
- Toll-like receptors 7 and 8 expression correlates with the expression of immune biomarkers and positively predicts the clinical outcome of patients with melanoma
- (2017) Moucheng Zhang et al. OncoTargets and Therapy
- A TLR3-Specific Adjuvant Relieves Innate Resistance to PD-L1 Blockade without Cytokine Toxicity in Tumor Vaccine Immunotherapy
- (2017) Yohei Takeda et al. Cell Reports
- Toll-Like Receptor 3 Signal in Dendritic Cells Benefits Cancer Immunotherapy
- (2017) Misako Matsumoto et al. Frontiers in Immunology
- Toll-Like Receptor Ligands and Interferon-γ Synergize for Induction of Antitumor M1 Macrophages
- (2017) Elisabeth Müller et al. Frontiers in Immunology
- Regulatory T cells in cancer immunotherapy
- (2016) Atsushi Tanaka et al. CELL RESEARCH
- Application potential of toll-like receptors in cancer immunotherapy
- (2016) Ming Shi et al. MEDICINE
- Damage-associated molecular patterns in cancer: a double-edged sword
- (2016) C Hernandez et al. ONCOGENE
- Toll-like receptor-5 agonist, entolimod, suppresses metastasis and induces immunity by stimulating an NK-dendritic-CD8+T-cell axis
- (2016) Craig M. Brackett et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Deconstructing innate immune signaling in myelodysplastic syndromes
- (2015) Melinda E. Varney et al. EXPERIMENTAL HEMATOLOGY
- TLR7 and TLR8 expression increases tumor cell proliferation and promotes chemoresistance in human pancreatic cancer
- (2015) TANJA GRIMMIG et al. INTERNATIONAL JOURNAL OF ONCOLOGY
- Mutation and expression analysis of the IDH1, IDH2, DNMT3A, and MYD88 genes in colorectal cancer
- (2014) Wen-Liang Li et al. GENE
- Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
- (2014) Roy S. Herbst et al. NATURE
- PD-1 blockade induces responses by inhibiting adaptive immune resistance
- (2014) Paul C. Tumeh et al. NATURE
- Induction of Antigen-Specific Immunity with a Vaccine Targeting NY-ESO-1 to the Dendritic Cell Receptor DEC-205
- (2014) M. V. Dhodapkar et al. Science Translational Medicine
- Intratumoral injection of Clostridium novyi-NT spores induces antitumor responses
- (2014) N. J. Roberts et al. Science Translational Medicine
- Myeloid-Derived Suppressor Cells in Cancer: Therapeutic, Predictive, and Prognostic Implications
- (2014) C. Marcela Diaz-Montero et al. SEMINARS IN ONCOLOGY
- Toll-Like Receptor 9 in Breast Cancer
- (2014) Jouko Sandholm et al. Frontiers in Immunology
- Toll-Like Receptor Signaling Pathways
- (2014) Takumi Kawasaki et al. Frontiers in Immunology
- Different Toll-Like Receptor Expression Patterns in Progression toward Cancer
- (2014) Lauri Jouhi et al. Frontiers in Immunology
- Toll-Like Receptor-4 Modulation for Cancer Immunotherapy
- (2014) Shanjana Awasthi Frontiers in Immunology
- Toll-Like Receptors and Prostate Cancer
- (2014) Shu Zhao et al. Frontiers in Immunology
- Toll-Like Receptors and Cancer: MYD88 Mutation and Inflammation
- (2014) James Q. Wang et al. Frontiers in Immunology
- Beyond MyD88 and TRIF Pathways in Toll-Like Receptor Signaling
- (2014) Vincent Piras et al. Frontiers in Immunology
- Dendritic cells matured in the presence of TLR ligands overcome the immunosuppressive functions of regulatory T cells
- (2014) Erik Berk et al. OncoImmunology
- TLR agonists: our best frenemy in cancer immunotherapy
- (2013) Sabina Kaczanowska et al. JOURNAL OF LEUKOCYTE BIOLOGY
- MyD88 in DNA Repair and Cancer Cell Resistance to Genotoxic Drugs
- (2013) Alain Kfoury et al. JNCI-Journal of the National Cancer Institute
- Repressing DNA Repair to Enhance Chemotherapy: Targeting MyD88 in Colon Cancer
- (2013) E. A. Williamson et al. JNCI-Journal of the National Cancer Institute
- Inhibition of CD4+CD25+ Regulatory T Cell Function and Conversion into Th1-Like Effectors by a Toll-Like Receptor-Activated Dendritic Cell Vaccine
- (2013) Major K. Lee et al. PLoS One
- Expression of Toll-like receptor-9 is associated with poor progression-free survival in prostate cancer
- (2013) MARJA-RIITTA VÄISÄNEN et al. Oncology Letters
- Prolonged subcutaneous administration of 852A, a novel systemic toll-like receptor 7 agonist, to activate innate immune responses in patients with advanced hematologic malignancies
- (2012) Brenda J. Weigel et al. AMERICAN JOURNAL OF HEMATOLOGY
- The Effects of TLR Activation on T-Cell Development and Differentiation
- (2012) Bo Jin et al. Clinical & Developmental Immunology
- The application of Toll like receptors for cancer therapy
- (2012) Eui Young So et al. International Journal of Biological Sciences
- Alarmins: awaiting a clinical response
- (2012) James K. Chan et al. JOURNAL OF CLINICAL INVESTIGATION
- Hallmarks of Cancer: The Next Generation
- (2011) Douglas Hanahan et al. CELL
- TLR2 Stimulation Drives Human Naive and Effector Regulatory T Cells into a Th17-Like Phenotype with Reduced Suppressive Function
- (2011) M. H. Nyirenda et al. JOURNAL OF IMMUNOLOGY
- Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia
- (2011) Xose S. Puente et al. NATURE
- Intracerebral administration of CpG oligonucleotide for patients with recurrent glioblastoma: a phase II study
- (2011) A. Carpentier et al. NEURO-ONCOLOGY
- Overexpression of TLR3, TLR4, TLR7 and TLR9 in esophageal squamous cell carcinoma
- (2011) Ilyar Sheyhidin WORLD JOURNAL OF GASTROENTEROLOGY
- Oncogenically active MYD88 mutations in human lymphoma
- (2010) Vu N. Ngo et al. NATURE
- The paradoxical effect of bevacizumab in the therapy of malignant gliomas
- (2010) E. M. Thompson et al. NEUROLOGY
- Toll-like receptor agonists in cancer therapy
- (2009) Sylvia Adams Immunotherapy
- HMGB1 Mediates Endogenous TLR2 Activation and Brain Tumor Regression
- (2009) James F Curtin et al. PLOS MEDICINE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More